Closed and semi-automated processing of CAR T cells

Product variability and manufacturing cost remain challenges in the widespread offering of CAR-T therapies to patients. In this application note, learn more about a robust end-to-end CAR-T cell therapy protocol for cGMP-compliant commercial manufacturing.

There is considerable excitement surrounding the treatment potential of T cell immunotherapies. Despite the clinical success of chimeric antigen receptor (CAR)-T cells, there remain challenges associated with routinely offering these products as treatment alternatives. These challenges include the costly manufacturing process relying on lengthy and complex open workflows with high manual labor requirements that influence product variability.

This application note describes the details of a robust CAR-T cell manufacturing workflow that can be adapted for cGMP compliance in commercial production of CAR-T cells. This semi-automated, closed CAR-T process achieves 1 × 10¹⁰ expanded T cells with more than 80% enhanced green fluorescent protein (eGFP) transduction efficiency across an 8-day manufacturing process.

This content was supplied by Cytiva.

AssetStream.aspx?mediaformatid=10061&destinationid=10016&assetid=31050